Merck KGaA (FRA:MRK) has been given a €100.00 ($119.05) price objective by equities research analysts at J P Morgan Chase & Co in a research note issued to investors on Tuesday. The brokerage currently has a “neutral” rating on the healthcare company’s stock. J P Morgan Chase & Co’s price objective points to a potential upside of 11.31% from the stock’s previous close.

A number of other equities research analysts have also weighed in on MRK. Nord/LB set a €98.00 ($116.67) price objective on shares of Merck KGaA and gave the stock a “neutral” rating in a report on Friday. Oddo Bhf set a €125.00 ($148.81) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Friday, September 29th. Warburg Research set a €115.00 ($136.90) price objective on shares of Merck KGaA and gave the stock a “buy” rating in a report on Tuesday, September 26th. Berenberg Bank set a €109.00 ($129.76) price target on shares of Merck KGaA and gave the stock a “neutral” rating in a research report on Friday, August 18th. Finally, Kepler Capital Markets set a €119.00 ($141.67) price target on shares of Merck KGaA and gave the stock a “buy” rating in a research report on Thursday, September 21st. Twelve investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of €107.81 ($128.34).

Shares of Merck KGaA (FRA MRK) opened at €89.84 ($106.95) on Tuesday. Merck KGaA has a fifty-two week low of €87.33 ($103.96) and a fifty-two week high of €115.00 ($136.90).

ILLEGAL ACTIVITY WARNING: “J P Morgan Chase & Co Analysts Give Merck KGaA (MRK) a €100.00 Price Target” was originally reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this article on another site, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/12/j-p-morgan-chase-100-00-price-target.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Stock Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related stocks with our FREE daily email newsletter.